PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 22, 2026International Journal of Molecular Sciences2 citationsOpen Access

Liquid Biopsies in HNSCC: Current Landscape and Emerging Opportunities in the Era of HPV Stratification

View Full Paper
APAkshaya PoonepalleGeorgia Institute of TechnologyJYJianqiang YangEmory UniversityNSNabil F. SabaEmory University

Key Points

  • The aim is to evaluate the current landscape and clinical utility of liquid biopsies in HNSCC, particularly concerning HPV status.
  • Reviewed evidence on circulating analytes: ctDNA, exosomes, and CTCs.
  • Discussed the clinical readiness and validation status of each analyte.
  • Outlined challenges in assay standardization and methodological reproducibility.
  • ctDNA shows promise for MRD detection and recurrence monitoring in HPV-positive HNSCC.
  • Exosomes and CTCs face technical hurdles and lack standardized protocols.
  • The presence of HPV-related ctDNA offers distinct clinical utility compared to HPV-negative tumors.

Abstract

Head and neck squamous cell carcinoma (HNSCC) is biologically and clinically dichotomous according to HPV status, a distinction that fundamentally dictates the design, implementation, and interpretation of liquid biopsy strategies. Conventional anatomical imaging lacks sufficient sensitivity for minimal residual disease (MRD) detection, contributing significantly to treatment failure and suboptimal clinical outcomes. This review provides a critical, evidence-based synthesis of the three principal circulating analytes, circulating tumor DNA (ctDNA), exosomes, and circulating tumor cells (CTCs), and their evolving roles in real-time, non-invasive molecular monitoring. Critically, the clinical readiness of these analytes differs substantially: while ctDNA, particularly HPV-related ctDNA, is approaching clinical validation for MRD detection and recurrence surveillance in HPV-positive HNSCC, exosomes and CTCs remain investigational tools hindered by ongoing technical challenges including lack of standardized assays, limited reproducibility across platforms, and insufficient prospective validation. We review how the presence of a clonal, virally derived DNA target in HPV-positive HNSCC contrasts with the heterogeneous somatic mutational landscape of HPV-negative tumors, necessitating divergent analytical platforms and yielding distinct clinical utility profiles for MRD detection and recurrence surveillance. We further outline a pragmatic translational pathway focused on assay standardization, particularly for exosomes and CTCs where this foundational work is most urgently needed, integration of complementary multimodal liquid biopsy approaches, and rigorously designed prospective interventional clinical trials to establish clinical utility. Collectively, these efforts aim to transition HNSCC management from reactive, anatomy-based surveillance to proactive, molecularly guided precision oncology, with the potential to improve therapeutic decision-making and patient outcomes.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Poonepalle et al. (2026) studied this question.

synapsesocial.com/papers/69bf899af665edcd009e9760https://doi.org/10.3390/ijms27062847
Ask AI
Helpful
Bookmark
Share
View Full Paper